BlossomHill Therapeutics filed for a planned IPO targeting up to about $129 million, setting out the clinical path for BH-30643, a macrocyclic EGFR-targeting molecule positioned as a potential challenger to AstraZeneca’s Tagrisso in EGFR-mutant NSCLC. In its SEC filing, BlossomHill said BH-30643 is in a phase 1/2 trial and that it intends to use IPO proceeds to launch a “potentially registrational” phase 2 study, including a focus on patients with resistance tied to C797S-mediated mechanisms. The company also outlined development spending for additional assets, including a phase 1 program for BH-30236 aimed at a “CDC-like kinase” target in relapsed/refractory AML and higher-risk MDS. If BH-30643 advances as planned, the company is aiming to compete in a crowded EGFR-mutant treatment landscape where trial design and patient selection are central to differentiation.